MedPath

Doxycycline

Generic Name
Doxycycline
Brand Names
Acticlate, Adoxa, Apprilon, Atridox, Doryx, Doxy, Doxycin, Lymepak, Mondoxyne, Monodox, Morgidox, Okebo, Oracea, Periostat, Targadox, Vibramycin
Drug Type
Small Molecule
Chemical Formula
C22H24N2O8
CAS Number
564-25-0
Unique Ingredient Identifier
334895S862

Overview

Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.

Indication

Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria, including: It is also used to treat infections caused by the following gram-negative microorganisms:

Associated Conditions

  • Acinetobacter Infections
  • Anthrax
  • Bacterial Infection caused by Enterobacter aerogenes
  • Bartonellosis
  • Brucellosis
  • Campylobacter Infection
  • Chancroid
  • Chlamydia Trachomatis Infection
  • Early Lyme Disease
  • Granuloma Inguinale
  • Infection Due to Escherichia Coli
  • Inhalational Anthrax
  • Klebsiella Infections
  • Lymphogranuloma Venereum
  • Malaria caused by Plasmodium falciparum
  • Nongonococcal urethritis
  • Plague caused by Yersinia pestis
  • Psittacosis
  • Rectal infection caused by Chlamydia Trachomatis
  • Relapsing fever caused by Borrelia recurrentis
  • Respiratory Tract Infection Bacterial
  • Rickettsial infectious disorders
  • Severe Acne
  • Sexually Transmitted Infections (STIs)
  • Shigella Infection
  • Trachoma inclusion conjunctivitis
  • Tularemia
  • Vibrio Cholerae Infection
  • Acute Intestinal amebiasis
  • Susceptible Bacterial Infections
  • Uncomplicated endocervical infection
  • Uncomplicated urethral infection

Research Report

Published: Jul 18, 2025

A Comprehensive Monograph on Doxycycline (DB00254): Pharmacological Profile, Clinical Applications, and Safety Considerations

Introduction and Drug Identification

Overview and Classification

Doxycycline is a potent, broad-spectrum antibiotic belonging to the tetracycline class of antimicrobial agents.[1] Classified as a small molecule, it represents a significant advancement as a second-generation tetracycline, synthetically derived from its predecessor, oxytetracycline.[1] This specific chemical heritage confers a more favorable toxicity profile compared to first-generation tetracyclines, a factor that has contributed substantially to its widespread and enduring clinical use.[1]

The drug is approved for both human and veterinary applications and is also categorized as an investigational agent, reflecting a robust and ongoing pipeline of research into novel therapeutic uses.[1] Its clinical utility is notably multifaceted, extending well beyond its primary function as a bacteriostatic agent. Doxycycline possesses well-documented antiparasitic and anti-inflammatory properties, making it a versatile therapeutic tool capable of addressing a diverse range of pathological processes, from infectious diseases to chronic inflammatory conditions.[1]

Chemical and Physical Properties

The definitive identification of doxycycline is established through several key chemical and physical descriptors. It is uniquely identified by the Chemical Abstracts Service (CAS) Number 564-25-0 and the DrugBank Accession Number DB00254.[1]

Continue reading the full research report

Clinical Trials

View More Clinical Trials

Sign in to access the complete clinical trial database with detailed study information.

FDA Drug Approvals

View More FDA Approvals

Sign in to access additional FDA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Lake Erie Medical DBA Quality Care Products LLC
55700-122
ORAL
100 mg in 1 1
3/12/2019
Proficient Rx LP
63187-135
ORAL
100 mg in 1 1
1/1/2021
Par Pharmaceutical, Inc.
49884-727
ORAL
100 mg in 1 1
8/25/2022
Northwind Pharmaceuticals, LLC
51655-998
ORAL
100 mg in 1 1
6/13/2023
Prasco Laboratories
66993-815
ORAL
40 mg in 1 1
1/19/2024
NuCare Pharmaceuticals, Inc.
68071-3252
ORAL
100 mg in 1 1
2/22/2021
Zydus Pharmaceuticals USA Inc.
68382-710
ORAL
150 mg in 1 1
11/9/2022
Changzhou Pharmaceutical Factory
55488-0186
ORAL
100 mg in 1 1
10/28/2020
Cardinal Health 107, LLC
55154-8079
ORAL
100 mg in 1 1
6/11/2019
NuCare Pharmaceuticals,Inc.
68071-5232
ORAL
100 mg in 1 1
1/14/2022

EMA Drug Approvals

View More EMA Approvals

Sign in to access additional EMA-approved drug information with detailed regulatory data.

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

View More HSA Approvals

Sign in to access additional HSA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

View More NMPA Approvals

Sign in to access additional NMPA-approved drug information with detailed regulatory data.

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

View More PPB Approvals

Sign in to access additional PPB-approved drug information with detailed regulatory data.

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

View More TGA Approvals

Sign in to access additional TGA-approved drug information with detailed regulatory data.

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.